^
Association details:
| Biomarker: | DNMT3A mutation |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | Venclexta (venetoclax) (Bcl2 inhibitor) + sorafenib (Multi-tyrosine kinase inhibitor, pan-RAF inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
1945 Venetoclax, FLT3 Inhibitor and Decitabine in FLT3mut Acute Myeloid Leukemia: Subgroup Analysis of a Phase II Trial
Published date:
11/04/2020
Excerpt:
In 10 pts who were refractory to or relapsed after ‘triplet’ therapy, the most frequent mutations at screening were DNMT3A (4), IDH1/2 (4), and N/KRAS (3).... In our experience, DEC10-VEN + FLT3i is safe and effective for previously treated FLT3mut AML, and an excellent frontline option for older pts with treatment-naïve AML.
Secondary therapy:
decitabine
